Key Points
- Insider sale: Edward Stelmakh sold 1,388 shares on Dec. 19 at an average price of $13.51 for $18,751.88, reducing his stake by 1.08% to 126,830 shares (valued about $1.71M).
- Mixed fundamentals and outlook: OptimizeRx beat quarterly expectations (EPS $0.20 vs $0.03; revenue $26.07M vs $23.83M) but analysts forecast a -0.33 EPS for the fiscal year and sentiment is mixed, with an average rating of "Moderate Buy" and a $16.88 price target.
- Market snapshot: OPRX opened at $13.29 (down 1.6%), has a $247.7M market cap, a 52‑week range of $3.99–$22.25, and about 76.5% of shares held by institutions.
OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) insider Edward Stelmakh sold 1,388 shares of the firm's stock in a transaction on Friday, December 19th. The shares were sold at an average price of $13.51, for a total transaction of $18,751.88. Following the transaction, the insider directly owned 126,830 shares of the company's stock, valued at $1,713,473.30. The trade was a 1.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
OptimizeRx Stock Down 1.6%
Shares of OPRX stock opened at $13.29 on Tuesday. The company's fifty day simple moving average is $16.45 and its two-hundred day simple moving average is $15.97. OptimizeRx Corp. has a 52 week low of $3.99 and a 52 week high of $22.25. The stock has a market cap of $247.73 million, a P/E ratio of 33.78 and a beta of 1.10. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 0.20.
OptimizeRx (NASDAQ:OPRX - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.17. The firm had revenue of $26.07 million for the quarter, compared to analysts' expectations of $23.83 million. OptimizeRx had a return on equity of 6.37% and a net margin of 0.03%. Analysts predict that OptimizeRx Corp. will post -0.33 EPS for the current fiscal year.
Analyst Ratings Changes
OPRX has been the subject of a number of research reports. JMP Securities increased their target price on OptimizeRx from $20.00 to $23.00 and gave the company a "market outperform" rating in a research report on Friday, October 10th. Citigroup reaffirmed an "outperform" rating on shares of OptimizeRx in a research note on Friday, October 10th. Weiss Ratings reissued a "sell (d+)" rating on shares of OptimizeRx in a research note on Monday, December 15th. Stephens reduced their target price on shares of OptimizeRx from $20.00 to $17.00 and set an "equal weight" rating on the stock in a report on Monday, November 17th. Finally, Citizens Jmp increased their price target on shares of OptimizeRx from $23.00 to $24.00 and gave the company a "market outperform" rating in a report on Friday, November 7th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $16.88.
Get Our Latest Report on OptimizeRx
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of OPRX. Harvest Investment Services LLC purchased a new stake in shares of OptimizeRx in the third quarter valued at $3,441,000. Worth Venture Partners LLC purchased a new stake in OptimizeRx in the 3rd quarter worth about $220,000. Virtus Advisers LLC purchased a new stake in OptimizeRx in the 3rd quarter worth about $516,000. Qube Research & Technologies Ltd purchased a new position in shares of OptimizeRx during the third quarter valued at approximately $381,000. Finally, Parkman Healthcare Partners LLC boosted its position in shares of OptimizeRx by 0.4% during the third quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company's stock valued at $10,447,000 after buying an additional 2,188 shares during the period. 76.47% of the stock is owned by hedge funds and other institutional investors.
About OptimizeRx
(
Get Free Report)
OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.
The company's core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
